Bio-Techne Corporation
72.55USD
-0.0700 (-0.10%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TECH.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 1.1B | 1.2B | 1.2B | 1.2B | 1.3B | 1.4B |
| Q1 | 269.7M | 276.9M | 289.5M | 286.6M | 292.2M | — |
| Q2 | 271.6M | 272.6M | 297.0M | 295.9M | 307.8M | — |
| Q3 | 294.1M | 303.4M | 316.2M | 311.4M | — | — |
| Q4 | 301.3M* | 306.1M* | 317.0M* | 321.2M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 1.76 | 1.05 | .460 | 1.16 | 2.04 | 2.31 |
| Q1 | .550 | .310 | .210 | .240 | .448 | — |
| Q2 | .310 | .170 | .220 | .240 | .481 | — |
| Q3 | .430 | .310 | .140 | .320 | — | — |
| Q4 | .466* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .252* |
| -.111* |
| .348* |
| — |
| — |
Debt level and coverage